Articles related to GLYCEMIC CONTROL

The statin group experienced an average LDL-C reduction of 37.9%, according to the results of the single-center, prospective, randomized, single-blind SPORT study (Supplements, Placebo, or Rosuvastatin), while those who took dietary supplements experienced LDL-C changes similar to those in the placebo group. Additionally, rosuvastatin-treated patients experienced average decreases in triglycerides of 19% and total cholesterol of 24%. For any of the supplements, there were no differences in either total cholesterol or triglycerides when compared to placebo.

Among more than 200 adolescents 12 to 18 years of age over a 68-week period, nearly 75% of those in the treatment group experienced weight loss of > 5%, compared with only about 15% of those with placebo plus lifestyle intervention. GI adverse events were more common in the treatment group.

To combat weight gain after bariatric surgery, a single weekly 1-mg dose of semaglutide outperformed liraglutide at 3-mg daily. About half the semaglutide group were able to lose more than 10% of their body weight, versus about 1/3 for the liraglutide group.

Hyperglycemia is associated with poor clinical outcomes in critically ill patients. Most medical societies recommend less stringent glucose control, in the range of 140 to 180 mg/dL, for critically ill patients. In this population, although glucose management is essential, hypoglycemia is associated with increased mortality. Enhancing the amount of time glucose levels are in the target range and minimizing glycemic variability have been associated with improved outcomes in critically ill patients.